Get the Stockscreener App
128.12
0.13%
0.17
After Hours:
130.30
2.18
+1.70%
Inhibrx Biosciences Inc stock is traded at $128.12, with a volume of 411.96K.
It is up +0.13% in the last 24 hours and up +101.67% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$127.95
Open:
$128.95
24h Volume:
411.96K
Relative Volume:
1.38
Market Cap:
$1.87B
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-14.17
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
-1.95%
1M Performance:
+101.67%
6M Performance:
+55.73%
1Y Performance:
+939.09%
1-Day Range:
$125.53
$133.90
1-Week Range:
$122.61
$134.40
52-Week Range:
$10.84
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
128.12 | 1.87B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences urges sustained research to accelerate oncology breakthroughs - Traders Union
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today & Analysis - Gotrade
Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum - Yahoo Finance
INBX Price Today: Inhibrx Biosciences, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Large drugmakers eye Inhibrx cancer drugs valued over $8 billion, stock surges - MSN
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx gains as Stifel issues new buy based on lead assets - MSN
Inhibrx Biosciences president granted 50K options | INBX Insider Trading - Stock Titan
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans - Yahoo Finance
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital - MarketBeat
This Inhibrx Biosciences analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Inhibrx Biosciences commits to sustainability with new Earth Day measures - Traders Union
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
[ARS] Inhibrx Biosciences, Inc. SEC Filing - Stock Titan
Executive pay and board elections detailed in Inhibrx (INBX) 2026 proxy filing - Stock Titan
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges - Sahm
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4%Should You Buy? - MarketBeat
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study - The Globe and Mail
INBX (Inhibrx Biosciences Inc.) reports narrow Q4 2025 EPS beat, shares rise 6.16 percent on upbeat investor sentiment.Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Inhibrx: Spinoff Rumors Send Shares SoaringStunning Bull Run Can Continue (NASDAQ:INBX) - Seeking Alpha
INBX Stock Spikes As Ozekibart Data Fuel Bullish Targets - timothysykes.com
INBX Stock Jumps As Ozekibart Data Draws $150 Target - StocksToTrade
Exclusive: Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
INBX Soars As Ozekibart Data And $150 Target Fire Up Traders - timothysykes.com
Stifel raises Inhibrx Biosciences price target on trial optimism By Investing.com - Investing.com Canada
INBX Stock Jumps As Ozekibart Data And $150 Target Fuel Buzz - StocksToTrade
Inhibrx Biosciences stock surges on takeover interest report By Investing.com - Investing.com Canada
Inhibrx Biosciences (NASDAQ:INBX) Sets New 52-Week HighHere's What Happened - MarketBeat
INBX Stock Whipsaws Higher As Ozekibart Data Fuels Bullish Targets - timothysykes.com
Inhibrx Biosciences stock reaches all-time high of 147.85 USD By Investing.com - Investing.com Australia
INBX jumps after ozekibart colorectal cancer update and regulatory progress - Quiver Quantitative
Inhibrx Biosciences stock reaches all-time high of 147.85 USD - Investing.com
Inhibrx Biosciences Inc. posts narrow EPS beat no quarterly revenue disclosed - UBND thành phố Hải Phòng
Morning Market Movers: AGPU, INBX, HCAI, FLWS See Big Swings - RTTNews
Inhibrx cancer drug reportedly drawing interest of Merck and rivals - Seeking Alpha
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - BioSpace
INBX: Ozekibart plus FOLFIRI delivers durable efficacy and safety in late-line colorectal cancer - TradingView
INBX: Ozekibart plus FOLFIRI showed strong efficacy and safety in late-line CRC, supporting further trials - TradingView
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data - TipRanks
Inhibrx Provides Interim CRC Data: 20% ORR, 5.5M Median PFS; FDA BLA Submitted for Chondrosarcoma - TradingView
87% disease control lifts Inhibrx drug in late-line colorectal cancer - Stock Titan
Ozekibart data and BLA advance Inhibrx (NASDAQ: INBX) cancer pipeline - Stock Titan
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):